jurnalul român de psihofarmacologie romanian journal of ...

227. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of
iloperidone. A broad spectrum dopmine/serotonin/norepinephrine receptor antagonist for
the management of psychotic disorders. Neuropsychopharmacology 2001; 25:904-914.
228. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability and effect of
food on the pharmacokinetics of iloperidone (HP873), a potential atypical antipsychotic. J
Clin Pharmacol 1995; 35:713-720.
229. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Exp Opin Invest
Drugs 2000; 9:2935-2943.
230. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. Br J Psychiatry 1997; 171:125-130.
231. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhand S, Le Lorier J. Reduction of
health care resource utilization and costs following the use of risperidone for patients with
schizophrenia previously treated with standard antipsychotic therapy: a retrospective
analysis using the Saskatchewan Health Linkable Data Bases. Clinical Drug Investigation
1996; 11:289-299.
232. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hirshman L. Clozapine’s
effectiveness for patients in state hospitals: results from a randomized trial.
Psychopharmacology Bulletin 1996; 32:683-697.
233. Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: clinical outcome
predictors and cost-effectiveness in a naturalistic setting. Psychopharmacology Bulletin
1998; 34:75-81.
234. Foster RH, Goa KL. Risperidone: a pharmacoeconomic review of its use in schizophrenia.
Pharmacoeconomics 1998; 14:97-133.
235. Foster RH, Goa KL. Olanzapine: a pharmacoeconomic review of its use in schizophrenia.
Pharmacoeconomics 1999; 15:611-640.
236. Guest JF, Hart WM, Cookson RF, Lindstrom E. Pharmacoeconomic evaluation of longterm
treatment with risperidone for patients with chronic schizophrenia. Br J Med
Economics 1996; 10:59-67.
237. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a
comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol
2000; 15:245-255.
238. Hamilton SH, Revicki DA, Edgell ET, Genduso L, Tollefson G. Clinical and economic
outcomes of olanzapine compared with haloperidol for schizophrenia: results from a
randomized trial. Pharmacoeconomics 1999; 15:469-480.
239. Hart WM, Lindstrom E, Guest JF. Economic impact of the use of risperidone for the
treatment of chronic schizophrenia in Ireland. Irish J Psychiatry 1997; 16:12-16.
151